CP and COVID-19: Furthermore, while CP therapy for COVID-19 may provide a clinical benefit when it is given early in the course of the disease and when it contains high IgG titers, the optimal antibody titer for viral neutralization remains unknown; this must be addressed for future standardization of CP therapy protocols in clinical trials [27,29].